WILMINGTON, Del. - Shareholders say directors of Cephalon breached their fiduciary by rejecting a $73 per share, $5.7 billion buyout offer from Valeant Pharmaceuticals.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026